Tuesday, August 24, 2021 4:55:20 AM
In the fullness of time (my best guess is between 2 and 4 weeks from now), we will find out if the scenario I predict comes to pass. But if I could monetize my guess at a reasonable cost*, I would.
I emphasize that this is NOT a real PR, just my speculation:
"Innovation Pharmaceuticals announces results of Phase II study of brilacidin in COVID-19
Analysis of the top lines results of this 120 patient study of brilacidin plus Standard of Care versus placebo and Standard of Care has now been completed.
Encouragingly, brilacidin proved effective in a number of patients hospitalized with COVID-19. However these results failed to reach significance.
This failure to reach significance was due to a more robust and pronounced effect in the placebo group than was anticipated, and therefore the study was not sufficiently powered to produce a statistically significant result. Additionally the requirement to use a lower dose of brilacidin than that used in previous Phase II studies resulted in lower serum levels than perhaps were necessary.
However retrospective analyses of some patient sub-sets have revealed some promising and encouraging directions for future research. For example, one-legged patients from Minsk not requiring ventilator support did better on brilacidin than on placebo.
Investigation of these promising avenues will require a Phase IIB clinical trial program and we are in the process of discussions with various entities regarding funding for this program."
* The economics of shorting a pink sheet stock like IPIX are unsustainable, so virtually nobody does. I certainly don't.
"Nobody ever went broke underestimating the intelligence of the
American public."
H. L. Mencken
"It’s easier to fool people than to convince them that they have been fooled."
Anon
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM